Substance and claimed effects

The substance is the diagnostic process for adult male hypogonadism — when to test serum testosterone, how to confirm a low value, what reversible drivers to work up before labelling a man hypogonadal, and the downstream decision about whether to initiate testosterone replacement therapy (TRT) or to treat the underlying cause first. It is fundamentally a test → workup → decide sequence, not a substance the reader ingests. The claimed effects of getting it right are: avoiding overdiagnosis from a single non-fasting afternoon draw, identifying and reversing causes (obesity, opioids, untreated obstructive sleep apnoea, chronic illness) that recover endogenous testosterone without lifelong injections, preserving spermatogenesis when fertility matters, and — where TRT is indicated — selecting the right formulation and the right monitoring schedule for haematocrit, prostate-specific antigen, and symptom response Bhasin et al. 2018 Mulhall et al. 2018. The article covers consequences across energy, mood, sexual function, body composition, fertility, cardiovascular safety, fracture risk, and the cost/effort burden of lifelong therapy.

Evidence by addressing question

mechanism

The hypothalamic-pituitary-gonadal (HPG) axis is a three-tier feedback loop: gonadotropin-releasing hormone (GnRH) pulses from the hypothalamus drive luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary, which act on Leydig cells (testosterone synthesis) and Sertoli cells (spermatogenesis) respectively. Primary hypogonadism is testicular failure with elevated LH/FSH (low T despite high gonadotropin signal — Klinefelter syndrome, post-mumps orchitis, post-chemotherapy, post-traumatic). Secondary (hypogonadotropic) hypogonadism is hypothalamic-pituitary failure with low or inappropriately normal LH/FSH (obesity, opioids, sleep apnoea, hyperprolactinaemia, pituitary tumours, congenital Kallmann syndrome) Bhasin et al. 2018. The distinction is what the morning LH/FSH draw is for: it tells the clinician where the lesion sits and whether the cause is reversible.

Testosterone has a pronounced circadian rhythm, with peak concentrations between 06:00 and 10:00 and a trough by mid-afternoon that can be 20–25% lower in younger men (the amplitude attenuates with age but is still meaningful in clinical decision-making). It is also food-suppressed: a glucose load can drop total testosterone by ~25% within 1–2 hours. Both phenomena are why Bhasin et al. 2018 requires a fasting morning draw and why a single low value cannot be interpreted in isolation — about 30% of men with a hypogonadal-range first draw will have a normal repeat measurement on retest. Total testosterone is also tightly bound to sex hormone-binding globulin (SHBG), and SHBG itself is moved by age (up), obesity (down), insulin resistance (down), thyroid status (up in hyperthyroidism), oestrogen exposure, and chronic illness — so a borderline total testosterone in a man with low or high SHBG warrants a calculated free or bioavailable testosterone Bhasin et al. 2018.

Obesity drives secondary hypogonadism through three converging mechanisms: aromatase activity in adipose tissue converts testosterone to oestradiol, which feeds back negatively on the hypothalamus; insulin resistance suppresses SHBG; and adipose-derived inflammatory cytokines (TNF-α, IL-6) and leptin-resistance disrupt GnRH pulsatility Camacho et al. 2013. In the European Male Ageing Study, obesity carried an 8.7-fold relative risk of secondary hypogonadism vs normal-weight controls; weight loss of ~10% via diet recovered testosterone by ~84 ng/dL on average, and bariatric surgery–level weight loss recovered ~251 ng/dL Camacho et al. 2013. Opioids act through a different pathway: μ-receptor agonism in the hypothalamus inhibits GnRH within hours of a dose, and chronic exposure produces sustained hypogonadotropic hypogonadism in 19–86% of men depending on dose, formulation (long-acting worse than short-acting), and threshold used Kafel et al. 2025. Untreated obstructive sleep apnoea suppresses testosterone through fragmented sleep and intermittent nocturnal hypoxia, both of which blunt the early-morning LH surge that drives the daily testosterone peak Zhang et al. 2019.

evidence

The major endpoints that TRT has been tested against, in symptomatic men with biochemically confirmed low testosterone, come from the Testosterone Trials coordinated set (T-Trials) and the TRAVERSE programme.

The T-Trials randomised 790 men aged 65+ with a screening testosterone <275 ng/dL and at least one symptom of androgen deficiency to one year of transdermal testosterone gel vs placebo, with seven prespecified efficacy domains Snyder et al. 2016. Sexual function improved with a moderate effect (increased sexual activity, desire, erectile function — effect on intercourse satisfaction strongest); mood improved with a small but statistically significant effect on depressive symptoms; the Physical Function Trial primary endpoint (≥50 metre improvement in 6-minute walk distance) missed in its own substudy but improved when pooling across all three trials. Cognition and vitality showed no benefit. The magnitude matters: the sexual function effect was clinically meaningful but smaller than PDE5 inhibitors; the mood effect was smaller than SSRIs in men with major depression.

The TRAVERSE trial randomised 5,246 men aged 45–80 with two morning total testosterone values <300 ng/dL, symptoms of hypogonadism, and either established cardiovascular disease or high CV risk, to transdermal testosterone gel titrated to a target of 350–750 ng/dL vs placebo, with the primary endpoint of first major adverse cardiovascular event (cardiovascular death, non-fatal MI, non-fatal stroke) Lincoff et al. 2023. Over a median follow-up of 33 months, MACE occurred in 7.0% of testosterone-treated vs 7.3% placebo (HR 0.96, 96% CI 0.78–1.17), meeting non-inferiority. However, the testosterone group had a higher incidence of atrial fibrillation (3.5% vs 2.4%, HR 1.43), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury (2.3% vs 1.5%) — adverse signals that did not derail the primary endpoint but should not be ignored. The TRAVERSE fracture substudy then surprised the field: testosterone-treated men had a higher incidence of clinical fractures (3.5% vs 2.5%, HR 1.43, 95% CI 1.10–1.87) over a median 3.2 years of follow-up Snyder et al. 2024 — counter to the prior assumption that improving bone mineral density would translate into fewer fractures. The leading hypothesis is cortical-bone effects or behavioural changes (more activity → more falls), but the substudy was not designed to identify a mechanism.

The T4DM trial tested whether TRT can prevent type 2 diabetes in 1,007 men aged 50–74 with waist circumference ≥95 cm, impaired glucose tolerance, and total testosterone ≤14.0 nmol/L (≈404 ng/dL) but no defined hypogonadism, all enrolled in a 2-year lifestyle programme Wittert et al. 2021. Testosterone undecanoate injections every 3 months halved progression to type 2 diabetes (12% vs 21%) on top of the lifestyle programme. Importantly, this is a prevention trial in functionally hypogonadal men with diabetes risk — not a TRT-for-symptoms trial — and it does not extend to men who are not pre-diabetic or who have not concurrently committed to weight loss.

On the FDA regulatory side: in March 2015 the FDA added a boxed warning about possible cardiovascular risk and restricted approved indications to classical hypogonadism (genetic, structural, post-treatment); in 2025, following TRAVERSE, the FDA removed the cardiovascular boxed warning while retaining the limitation-of-use language for age-related testosterone decline and adding a new blood-pressure warning based on ambulatory blood-pressure monitoring substudies FDA 2025.

protocol

The diagnostic protocol that the two major guidelines converge on:

1. Confirm symptoms before testing. Bhasin et al. 2018 and Mulhall et al. 2018 both recommend against screening asymptomatic men. The most specific symptoms in adult men are reduced libido, fewer morning erections, and erectile dysfunction; less specific symptoms (fatigue, low mood, brain fog, reduced exercise tolerance) overlap with sleep disorders, depression, anaemia, and thyroid disease and should not drive the workup alone.
2. Initial test: fasting morning total testosterone, two occasions. Draw between 07:00 and 10:00, fasted (glucose suppresses T by ~25%), with a CDC-standardised liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay where available. Repeat on a separate morning before diagnosing — ~30% of men with a first low draw will have a normal repeat Bhasin et al. 2018.
3. Diagnostic threshold: total T <264 ng/dL (<9.2 nmol/L) by harmonised reference range derived from healthy young men Bhasin et al. 2018. The AUA uses 300 ng/dL as a working threshold for clinical decision-making Mulhall et al. 2018. The borderline range 264–400 ng/dL is the grey zone where free or bioavailable testosterone, repeat measurement, and clinical judgement carry weight.
4. If SHBG-altering conditions are present, calculate free T. Obesity, insulin resistance, ageing, thyroid disease, hepatic disease, anti-epileptic drugs, and chronic illness shift SHBG; in these populations, free or bioavailable testosterone (calculated from total T, SHBG, and albumin) is the more informative number Bhasin et al. 2018.
5. Distinguish primary vs secondary: measure LH and FSH. High LH/FSH with low T → primary (testicular) hypogonadism — work up cause (testicular ultrasound if recent change, karyotype if Klinefelter suspected). Low or normal LH/FSH with low T → secondary (hypothalamic-pituitary) hypogonadism — measure prolactin, ferritin (haemochromatosis), iron studies, and pituitary imaging if T <150 ng/dL, severe symptoms, or pituitary signs present Bhasin et al. 2018.
6. Work up and address reversible drivers before initiating TRT. Obesity (weight loss), opioids (taper if clinically feasible), untreated OSA (sleep study and CPAP), excessive alcohol, glucocorticoids, anabolic steroid history, and uncontrolled diabetes are all reversible or partially reversible drivers. Weight loss of ~10% via diet recovers ~84 ng/dL on average; bariatric surgery recovers ~251 ng/dL Camacho et al. 2013.
7. If TRT is indicated, decide formulation by patient preference and side-effect profile. Topical gels (daily, steady levels, transfer risk to women/children), short-acting IM injections (every 1–2 weeks, peak-trough swing in mood and energy), long-acting IM testosterone undecanoate (every 10 weeks, requires pulmonary oil microembolism monitoring), subcutaneous pellets (every 3–6 months, surgical placement), oral testosterone undecanoate (twice-daily with food, lipid effects). All target a serum T in the mid-normal young-adult range (~400–700 ng/dL) Bhasin et al. 2018 Mulhall et al. 2018.
8. Monitoring schedule: total T at 3 and 6 months and then annually; haematocrit at baseline, 3 and 6 months, and annually (hold or reduce dose if Hct >54%); prostate-specific antigen (PSA) at baseline, 3 and 12 months, then per local prostate-cancer screening practice (digital rectal exam at baseline and 12 months for men 40+); symptom reassessment at 3 and 6 months — discontinue if no symptomatic benefit Bhasin et al. 2018.

contraindications

Absolute contraindications per Bhasin et al. 2018: active prostate or breast cancer; uninvestigated palpable prostate nodule or PSA >4 ng/mL (or >3 in higher-risk groups); haematocrit >48% at baseline; thrombophilia or recent thromboembolic event; severe untreated obstructive sleep apnoea; severe lower urinary tract symptoms (AUA symptom score >19); uncontrolled or poorly controlled congestive heart failure; major adverse cardiovascular event within the prior 3–6 months. Relative contraindications: desire for current or near-term fertility (TRT suppresses spermatogenesis — see misconceptions and alternatives); polycythaemia history; well-controlled OSA on CPAP.

misconceptions

The four most commonly weaponised misconceptions in the consumer TRT marketplace:

• "Low T is just a number on a chart." Reference ranges from many commercial labs include men with subclinical illness and obesity, lowering the reported lower limit to 240–250 ng/dL or even lower. Bhasin et al. 2018 derived 264 ng/dL from a CDC-harmonised healthy young-men cohort. A reading of 350 ng/dL is "normal" by most lab cards and not low by the Endocrine Society threshold.
• "TRT preserves fertility / doesn't affect sperm." Exogenous testosterone suppresses LH and FSH via negative feedback, collapsing intratesticular testosterone by ~94% within weeks Coviello et al. 2005 and rendering most men azoospermic or severely oligospermic within 3–6 months. The WHO contraceptive trials of weekly testosterone enanthate produced azoospermia in ~75% of men within 6 months. Sperm recovery after discontinuation takes 6–18 months in most men and may be incomplete in older men or after prolonged use.
• "TRT reverses age-related testosterone decline." The age-related decline in healthy non-obese men is ~1% per year and the majority of "low T" in middle-aged men is driven by obesity and comorbidities, not pure ageing Camacho et al. 2013. The secular decline in population testosterone is real (Travison 2007 documented an age-independent drop of ~1% per year across MMAS waves) Travison et al. 2007, but is best addressed at the population level by fixing obesity and lifestyle rather than at the individual level by exogenous T.
• "TRT prevents cardiovascular disease and dementia." TRAVERSE established cardiovascular non-inferiority but not benefit, and signalled increased atrial fibrillation, pulmonary embolism, and (in the fracture substudy) clinical fracture Lincoff et al. 2023 Snyder et al. 2024. The T-Trials cognition substudy showed no benefit on cognition in older men Snyder et al. 2016.

alternatives

For men with secondary hypogonadism who want to preserve fertility, or who prefer to avoid lifelong exogenous testosterone, selective estrogen receptor modulators (SERMs) and human chorionic gonadotropin (hCG) raise endogenous testosterone by working with the HPG axis instead of suppressing it.

• Clomiphene citrate (25–50 mg every other day or daily) blocks oestrogen negative feedback at the hypothalamus, raising LH and FSH and therefore endogenous testosterone and spermatogenesis. Off-label use; widely prescribed in fertility-oriented practices. Response rates highest in younger men with intact testicular function (secondary hypogonadism) Krzastek & Smith 2020.
• Enclomiphene citrate (the active trans-isomer of clomiphene) raises testosterone to similar levels as topical gels while preserving sperm concentration in phase II trials; FDA approval has been held up by analytical concerns Krzastek & Smith 2020.
• hCG (typically 500–1500 IU SC 2–3× weekly) directly stimulates Leydig-cell testosterone production and maintains intratesticular testosterone. Used either as monotherapy or co-administered with TRT to preserve fertility Coviello et al. 2005.
• Treat the underlying cause is the alternative the guidelines lead with: weight loss for obesity-driven hypogonadism, opioid taper for OPIAD, CPAP for OSA, treatment of pituitary tumour or hyperprolactinaemia. These approaches address cause rather than effect and don't lock the man into a lifelong therapy.

practicalities

The diagnostic workup itself is one or two morning blood draws (≈$50–$200 out-of-pocket if uninsured; covered by most insurance with appropriate clinical indication), plus LH/FSH, prolactin, and CBC on the confirmatory draw. If TRT is initiated, the ongoing cost varies dramatically by formulation: generic IM testosterone cypionate runs ~$50–$200/year cash; brand-name topical gels (AndroGel, Testim, Axiron) ~$300–$600/month cash, often ~$30–$100/month with insurance; long-acting injections (Aveed) ~$1,500–$3,000/year cash; pellets (Testopel) ~$1,000–$2,000 per insertion every 3–6 months. The monitoring schedule adds 2–3 blood draws per year for the first year plus annually, prostate-specific antigen, and clinical follow-up — a few hundred dollars annually. Insurance coverage in the US is conditional on documented biochemical hypogonadism (typically two low morning T values) plus a recognised aetiology; "wellness" or "anti-aging" TRT is typically cash-pay through specialty clinics that charge $1,000–$3,000 per year on top of the medication.

Effort is non-trivial: a daily gel application that must be allowed to dry and that risks transfer to women and children in the household; or a weekly to bi-weekly injection (often self-administered intramuscular or subcutaneous); or a quarterly clinic visit. The lifetime commitment piece is the under-appreciated one — discontinuation typically returns the man to his pre-TRT testosterone within weeks, with the symptomatic crash often more disruptive than the original low T.

failure-modes

• Diagnosis from a single afternoon, non-fasting draw. The most common error in primary-care TRT prescribing. ~30% of "low" first-draws normalise on retest Bhasin et al. 2018; an afternoon non-fasting draw can be 25–30% below the same man's morning fasting value purely from diurnal variation and glucose suppression.
• Treating a number, not symptoms. A man with a screened T of 280 ng/dL and no symptoms specific to androgen deficiency (libido, morning erections, erectile dysfunction) does not meet diagnostic criteria for hypogonadism, regardless of how he feels.
• Skipping the reversible-driver workup. Initiating TRT on an obese man with untreated OSA without first addressing weight, sleep, and (if applicable) opioids commits him to lifelong therapy for a condition that may have been substantially reversible.
• Not measuring LH/FSH. A young man with primary hypogonadism may have an underlying pituitary tumour or haemochromatosis that needs treatment in its own right; the diagnosis is missed if the workup stops at total T.
• Not warning about fertility. Men of reproductive age who are not counselled about TRT's suppressive effect on spermatogenesis and who later attempt conception face months-to-years of recovery and may need hCG or clomiphene rescue therapy.
• Polycythaemia neglect. Haematocrit rises with TRT (more on injections than gels); >54% requires phlebotomy or dose reduction and is a thrombosis risk.

audience

The article scope is adult men, predominantly ages 30–70. Adolescent hypogonadism (Klinefelter, Kallmann, delayed puberty) is a paediatric-endocrine question and out of scope. Men >75 are under-represented in the trials (T-Trials excluded high-CV-risk older men; TRAVERSE was 45–80). Men actively trying to conceive should not initiate TRT and should be steered to clomiphene, enclomiphene, or hCG (see alternatives). Men with prior prostate cancer treated with curative intent are a special-counselling group — TRT is not absolutely contraindicated but requires urology co-management.

stakes

The downside cases divide into two: untreated true hypogonadism (loss of libido, persistent fatigue, depressed mood, loss of muscle mass and bone density with eventual fracture risk, possible cardiometabolic decline through worsened insulin resistance) and iatrogenic harm from inappropriate TRT (lifelong therapy for a reversible condition, suppressed fertility, elevated haematocrit and thrombosis risk, the atrial fibrillation and fracture signals from TRAVERSE, the cost burden, the loss of the off-ramp once initiated). The asymmetry is informative: a man who waits 6 months to confirm hypogonadism, address reversible drivers, and choose deliberately loses very little; a man who is started on TRT inappropriately loses the option to back out without symptom rebound.

payoff

In a properly diagnosed symptomatic hypogonadal man treated to mid-normal range: sexual function improves at 3–6 months (moderate effect — better than placebo, smaller than PDE5i); mood improves at 3–6 months (small but measurable effect on depressive symptoms); energy and exercise tolerance improve in some men, with the response heavily variable; body composition shifts toward more lean mass and less fat over 6–12 months Snyder et al. 2016. The TRAVERSE programme established that, in properly selected men, MACE rates are not elevated Lincoff et al. 2023 — a meaningful re-anchor of the cardiovascular conversation after the 2015 boxed warning. But the dramatic transformations promised by direct-to-consumer TRT clinics ("become the man you used to be at 25") are not what the controlled trials produce; the response in real hypogonadism is real but moderate.

history

Testosterone was first isolated in 1935 and synthesised the same year (a Nobel-winning effort by Butenandt and Ruzicka). Therapeutic use grew slowly through the 1950s–1990s, indicated narrowly for classical hypogonadism. The modern TRT marketplace was created by direct-to-consumer advertising of testosterone gels in the mid-2000s (AndroGel, Testim) targeting "Low T" symptoms in otherwise healthy ageing men. US prescriptions tripled between 2001 and 2011. Two observational studies in 2013–2014 (Vigen JAMA 2013; Finkle PLOS ONE 2014) reported elevated cardiovascular events; the FDA convened an advisory committee in September 2014 that voted 20–1 to restrict the indication, and added a boxed warning in March 2015. TRAVERSE was the FDA-mandated post-marketing cardiovascular safety trial that ran 2017–2022 and reported in 2023 Lincoff et al. 2023; the FDA removed the boxed warning in 2025 FDA 2025. The Travison 2007 documentation of a population-level decline in testosterone independent of age Travison et al. 2007 is the other major historical anchor — it is repeatedly cited in popular-press defences of widespread TRT, often without the caveat that the decline tracks closely with the rise in obesity and other lifestyle factors.

out-of-scope

Topics adjacent to this entry that warrant their own treatment: obesity and metabolic health as drivers of male hormonal dysfunction; obstructive sleep apnoea testing and CPAP; opioid tapering; PDE5 inhibitors for erectile dysfunction as a separate intervention; female testosterone use (a different evidence base, different indications); transgender hormone therapy (overlapping pharmacology, fundamentally different decision frame); anabolic steroid use and recovery from suppression; bone density screening and fracture prevention in men.

The credibility range

Optimist case

Testosterone deficiency is genuinely underdiagnosed in primary care because (a) generalists do not run a structured workup, (b) symptoms are non-specific and easily attributed to ageing or depression, and (c) the diagnostic threshold matters: a man with a confirmed morning fasting T of 250 ng/dL and characteristic symptoms is hypogonadal and the literature supports treatment. In appropriately selected men, the T-Trials demonstrated real moderate benefits on sexual function and mood, the TRAVERSE programme removed the cardiovascular fear that had suppressed prescribing for a decade, the T4DM trial showed metabolic benefits in pre-diabetic obese men, and modern preparations (gels, subcutaneous injections) make adherence easy. The Travison secular decline is real and reflects something genuinely worsening at the population level. For the right patient — confirmed hypogonadism with classical symptoms, no fertility concerns, no contraindication — TRT is one of the better-evidenced interventions in male medicine.

Skeptic case

The vast majority of "Low T" prescribing in the US is not for confirmed hypogonadism. It is age-related testosterone decline in obese men with comorbidities, marketed by direct-to-consumer clinics that bill cash and skip the reversible-driver workup. The effect sizes in the T-Trials were moderate at best — smaller than PDE5 inhibitors for sexual function, smaller than SSRIs for depression. TRAVERSE established non-inferiority on MACE but signalled excess atrial fibrillation, pulmonary embolism, acute kidney injury, and (in the fracture substudy) higher clinical fracture rates — adverse signals that would not be tolerated in most other prescription decisions. The fertility cost is irreversible in some men. The lifetime cost is meaningful. The off-ramp is poor — discontinuation produces a symptom rebound that often locks the man in. And the underlying driver in most cases (obesity, untreated OSA, opioid use) is something that, if addressed, reverses the hypogonadism without lifelong injection.

Author's call

Both positions are right about a different patient. For a man who clears the diagnostic bar — confirmed morning fasting T below the Endocrine Society threshold on two occasions, classical symptoms, an identified aetiology, a completed reversible-driver workup, no fertility concerns, no contraindication — TRT is a reasonable, moderately-evidenced therapy that the major guidelines support. For the much larger population of men whose first low draw came from an afternoon non-fasting blood test, who are obese and untreated for OSA, who are still trying to conceive, or who were prescribed by a direct-to-consumer clinic that charges cash — the correct call is the workup, not the prescription. The entry frames the diagnostic process as the central decision point: doing the testing properly, addressing reversible drivers, and treating the prescription itself as a deliberated decision rather than a presumed outcome. action: decide. evidence: 4 on the diagnostic workup (guidelines and major trials converge); controversy: 3 on TRT itself (legitimate active debate on age-related indication, fracture signal, and DTC prescribing).

Stakeholder and incentive map

• Pharmaceutical manufacturers (AbbVie, Endo, Acerus, Antares, Upsher-Smith) sponsor the testosterone gel and injection market; they funded TRAVERSE under FDA mandate and benefit from the 2025 boxed-warning removal.
• Direct-to-consumer TRT clinics (Hone, Defy Medical, Marek Health, countless local "men's health" clinics) have a structural incentive to prescribe — their business model depends on patient throughput, not diagnostic restraint. Many use telemedicine and skip the LH/FSH and reversible-driver workup.
• Endocrine Society and American Urological Association issue restrictive guidelines emphasising confirmatory testing, symptom requirements, and reversible-driver workup. The two guidelines are closely aligned Bhasin et al. 2018 Mulhall et al. 2018.
• FDA took a restrictive stance in 2015 (boxed warning, indication restriction) and a more permissive stance in 2025 (boxed warning removal) based on TRAVERSE FDA 2025.
• Reproductive medicine community sees the downstream consequence — men presenting at fertility clinics post-TRT — and is the loudest voice on the fertility cost.
• Cardiology community remains divided: TRAVERSE's primary endpoint was reassuring; the atrial fibrillation and fracture signals are not.
• Men's health communities and podcasts (Huberman, Attia, the broader "biohacker" space) frame TRT as under-prescribed and the diagnostic threshold as too restrictive; they overlap commercially with TRT clinics.

Population variability

• Age. The age-related decline in healthy non-obese men is ~1% per year; symptoms attributable to androgen deficiency become more common in the 50s and 60s. Older men in the T-Trials had smaller absolute responses than younger trial participants.
• Body composition. Obesity is the single largest driver of secondary hypogonadism in modern populations; an obese 45-year-old's low T is best treated with weight loss first.
• Race and ethnicity. Most testosterone reference range studies have been derived from predominantly White cohorts; reference ranges may be modestly different across populations but the symptomatic threshold is more robust than the biochemical one.
• Comorbidities. Type 2 diabetes, metabolic syndrome, chronic kidney disease, cirrhosis, HIV/AIDS, and chronic opioid use are independent drivers; men on long-term high-dose opioids have OPIAD prevalence as high as 50–90% Kafel et al. 2025.
• Reproductive intent. Men trying to conceive should not be on TRT.
• Genetic carriers. Klinefelter (47,XXY) carriers (~1 in 600 men) have primary hypogonadism from birth and a different lifetime treatment frame.

Knowledge gaps

What the evidence base does not yet tell us:

• The fracture mechanism. The TRAVERSE fracture substudy found higher fracture rates with no clear mechanism — cortical bone effects, behavioural changes, falls risk. A mechanistic substudy is needed Snyder et al. 2024.
• Long-term cardiovascular safety beyond 3 years. TRAVERSE follow-up was a median 33 months; the atrial fibrillation signal needs longer-term confirmation.
• Optimal target range. Is mid-normal (400–700 ng/dL) actually optimal, or is the bottom of normal (300–400) safer for fracture and AF while still relieving symptoms? Not formally tested.
• Treatment of "borderline" hypogonadism (300–400 ng/dL with symptoms). The trials enrolled men below 275–300 ng/dL; the grey zone is under-studied.
• Comparative effectiveness of SERMs vs TRT in secondary hypogonadism. Clomiphene and enclomiphene are widely used off-label but lack head-to-head trials with TRT for symptom response.
• Discontinuation pathways. What happens when men stop TRT after 5–10 years — symptom rebound severity, endogenous recovery rates, long-term sequelae — is poorly characterised.
• OSA-driven hypogonadism reversal. CPAP's effect on testosterone is mixed in trials; some subgroups (severe OSA in severely obese men) appear to respond, others do not Zhang et al. 2019.

Scope and framing. The brief named testing, the reversible-driver workup, treatment selection, fertility preservation and long-term TRT decisions. All five are covered. The article is framed around the diagnostic decision rather than around TRT itself because the dossier surfaced that the most consequential failure mode in this space is mis-diagnosis (single afternoon draw, no LH/FSH, no driver workup, lifetime prescription) rather than poor TRT execution. The action: decide + protocol structure tracks that framing.

What was excluded.

• Female testosterone use — completely different evidence base, indication, and dosing; warrants its own entry.
• Transgender hormone therapy — overlapping pharmacology but a fundamentally different decision frame, regulatory environment, and clinical pathway. Out of scope.
• Anabolic-steroid use and recovery from steroid-induced suppression — adjacent, common in younger men, but the population, doses and post-cycle therapy literature are distinct enough to deserve a separate entry. Flagged as a future-link candidate.
• Adolescent / paediatric hypogonadism (Klinefelter, Kallmann, delayed puberty) — paediatric endocrine territory; mentioned only in passing in the audience section.
• Detailed prostate cancer screening protocol — touched on as a contraindication to TRT and a monitoring obligation, but the screening decision itself is its own entry.
• Detailed bone density screening in men — flagged in out-of-scope as a future entry rather than expanded inline.

Rating difficulties.

• Longevity scored 2. Genuine tension between the TRAVERSE non-inferiority result (reassurance), the TRAVERSE fracture substudy (signal in the wrong direction), and the T4DM diabetes-prevention result (real but in a specific obese pre-diabetic subgroup, on top of lifestyle). The longevity win lives more in addressing reversible drivers than in TRT itself; the entry's framing captures that.
• Controversy scored 3. Could plausibly be 4 given the active DTC-clinic vs guideline-society fight, the diagnostic-threshold debate, and the fracture-signal interpretation argument. Held at 3 because the two major guidelines (Endocrine Society, AUA) substantially agree on the workup and the trial evidence base is not internally contested — the disputes are around interpretation and indication-stretching, not around the data.
• Energy scored 3 not 4. Trial effects in T-Trials were measurable but moderate; the 4 anchor ("substantial vitality difference, day after day") overstates the response in real-world properly-diagnosed populations. Holding 3 keeps the catalogue honest against the marketing hype.
• Focus scored 1 not 0. T-Trials cognition substudy was null, but subjective fog from genuine low T does lift for some men; trivial-positive rating reflects the lived-experience signal without overstating it.

Future-link candidates. sleep-apnea, obesity-and-low-testosterone, opioid-tapering, erectile-dysfunction, bone-density-screening-men, prostate-cancer-screening, anabolic-steroid-recovery, clomiphene-enclomiphene-for-hypogonadism (could split out if SERM use grows further).

Separate-entry candidates. The alternatives section had to compress clomiphene, enclomiphene and hCG into one paragraph each — each warrants its own entry once the catalogue is deep enough. The reversible-driver workup (weight, OSA, opioids) similarly compresses three substantial topics; the cross-links to their own future entries are the long-term solution.

Hard call on tone. The article is more skeptical of broad TRT prescribing than the typical men's-health blog and more skeptical than the DTC clinic ecosystem; it is closer to the guideline societies' position. This is the author's call from the credibility-range synthesis and is consistent with the meta scores (moderate, not transformative). If the editorial direction is to land more permissively (more aligned with the popular men's-health space), the changes would be in the misconceptions section and the second story in stakes.

What the brief named but the article does not dwell on. Treatment-formulation selection is touched on in the practicalities framing inside protocol and payoff rather than given its own addressing section — the formulation choice is real but smaller than the diagnostic decision in terms of consequences, and the article's centre of gravity is the decision before the prescription rather than the prescription itself. Reviewers who want a deeper formulation comparison (gel vs IM vs subcutaneous vs pellet vs oral undecanoate) could request a separate entry.